Hydralazine Induced Vasculitis: A Case Report

Title:Hydralazine Induced Vasculitis: A Case Report

Volume: 5

Author(s): Fathi Giurani*Mohamed Abdelgalil

Affiliation:

• Consultant Geriatric Medicine, Burjeel Medical City, Abu Dhabi, UAE

Abstract:

Background: Hydralazine has been used in the treatment of hypertension and heart failure for a long time. It has been associated with the development of Vasculitis and Drug induced lupus. This is a male patient in his sixties who was admitted at the hospital and prescribed hydralazine. He developed Hydralazine-induced lupus with Pancytopenia and renal failure. This case report has been written to raise awareness about the hydralazine side effects.

Case Presentation: This case report describes a 68-year-old male, transferred to our hospital for rehabilitation. He was tracheostomized. He is hypertensive with a history of CVA. BP was elevated during the admission. He has no family history of immunological diseases or any allergies. 6 months after hydralazine, the patient started to have a purpuric rash over the lower limbs and an elevated renal profile. Only Direct Coomb’s test was positive. He had hematuria and pancytopenia also. He was started on steroids and he became edematous. On March 2021, the hydralazine was stopped and the patient's blood tests improved, the rash disappeared and hematuria stopped. Unfortunately, he got fungemia and septicemia with pneumonia. He became hypotensive and anuric. The patient kept deteriorating and passed away.

Discussion: Hydralazine is not a first line choice for the treatment of hypertension. Common side effects include tachycardia and headache. It can also cause drug-induced lupus.

Conclusion: Hydralazine has been used in the treatment of hypertension and heart failure for a long time. It has been associated with the development of Vasculitis and Drug induced lupus.

Cite this article as:

Giurani Fathi*, Abdelgalil Mohamed, Hydralazine Induced Vasculitis: A Case Report, New Emirates Medical Journal 2024; 5 : e02506882229825 . https://dx.doi.org/10.2174/0102506882229825230928073826